Vopratelimab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameVopratelimab
Drug Alias NameVopratelimab - Jounce TherapeuticsJTX-2011
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInducible T-cell costimulator agonists
TargetsInducible T-cell costimulator
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaBulgariaCanada +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesJounce Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelgene CorpJounce Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A